ClinicalTrials.gg
RecruitingNCT07565961HOTUpdated Oct 7, 2026

HoLEP-ThuLEP - Comparing Lasers for BPH Surgery

An interventional study of Thulium Laser Enucleation of the Prostate (ThuLEP) and Holmium Laser Enucleation of the Prostate (HoLEP) in BPH (Benign Prostatic Hyperplasia), sponsored by Ludwig-Maximilians - University of Munich. Recruiting at 1 site in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Ludwig-Maximilians - University of Munich · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 7, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Prostatic Hyperplasia with a site in Germany — 2 open to participants now, 2 under way, none of them phase 3. Prostatic Hyperplasia · Germany.

Planned enrollment
22nd of 28
150 · median 450
Started
2026
the only one that year
No phase
4 of 32
1 open now
Registered
32nd of 32
by date

Among the 32 studies in Prostatic Hyperplasia with a site in Germany, this one is the 22nd largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2026, is one of 4 with no phase, and was the 32nd registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 32 studies in Prostatic Hyperplasia with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Prostatic Hyperplasia with a site in Germany, or all of them as a file.
02

Study summary

Benign prostatic hyperplasia (BPH) is a very common condition in older men. As the prostate enlarges, it can press on the urethra and make urination difficult. Typical symptoms include a weak urinary stream, frequent urination, getting up at night to urinate, and a feeling that the bladder is not fully empty. When medication is no longer sufficient, surgical removal of the inner part of the prostate ("enucleation") is the recommended treatment.

Two modern laser techniques are used for this operation. Holmium Laser Enucleation of the Prostate (HoLEP) is currently considered the reference standard, with very good long-term results and a low rate of re-operations. Thulium Laser Enucleation of the Prostate (ThuLEP) using a pulsed thulium laser is a newer alternative. Because the laser energy is delivered in short pulses, ThuLEP may allow more precise tissue cutting and better control of bleeding during surgery.

So far, only limited high-quality randomized data directly compare the two techniques, particularly for patient-reported outcomes such as urinary symptoms, continence, and erectile function.

Purpose of the study The HoT-Trial investigates whether ThuLEP is as effective as HoLEP for men who need surgery for an enlarged prostate, and whether there are differences in recovery, complication rates, urinary symptoms, continence, and erectile function after surgery.

Research question Does ThuLEP lead to a similar improvement in lower urinary tract symptoms (LUTS) as HoLEP 12 months after surgery, measured by the change in the International Prostate Symptom Score (IPSS)?

How the study works A total of 150 men aged 18 years or older with clinically relevant BPH, an IPSS of 8 or higher, a prostate volume above 40 ml, and an indication for surgery will take part. Each participant will be randomly assigned (1:1) to either ThuLEP or HoLEP. Participants are blinded to the assigned technique (single-blind design). Both procedures are established, guideline-recommended treatments; taking part in the study does not add any risks beyond standard care.

Before surgery, participants complete standardized questionnaires (IPSS, ICIQ-SF, IIEF) and undergo uroflowmetry and residual urine measurement. Surgery is performed according to randomization. Participants are then followed up in the urology outpatient clinic at discharge and at 3, 6, and 12 months after surgery. The same measurements and questionnaires are repeated at each visit.

Primary outcome Change in IPSS from baseline to 12 months after surgery.

Secondary outcomes Maximum urinary flow rate (Qmax) and post-void residual urine; continence (ICIQ-SF) and erectile function (IIEF); operative time, laser time, blood loss, transfusion rate; catheter indwelling time and length of hospital stay; peri- and postoperative complications graded by the Clavien-Dindo classification; and the rate of re-intervention or re-catheterization within 12 months.

Setting and timeline The study is conducted as a single-center trial at the Department of Urology, Ludwig-Maximilians-University Munich, Germany. Recruitment runs for approximately two years, with up to 12 months of follow-up per participant. The total study period is planned from April 2026 to April 2029.

By directly comparing the two laser enucleation techniques in a randomized setting, the HoT-Trial aims to help patients and physicians choose the most suitable surgical treatment for benign prostatic hyperplasia.

Read the detailed description

Background and rationale Benign prostatic syndrome (BPS) is among the most frequent urological diseases in older men and a leading cause of treatment-requiring lower urinary tract symptoms (LUTS). For moderately to severely enlarged prostates, endoscopic enucleation procedures have become the surgical gold standard. Holmium Laser Enucleation of the Prostate (HoLEP) is considered the reference technique, with excellent long-term functional outcomes and a low re-intervention rate.

Thulium Laser Enucleation of the Prostate (ThuLEP) using pulsed thulium laser technology (wavelength approximately 2013 nm) has been introduced as an alternative enucleation procedure. The high absorption in water enables precise tissue dissection while allowing effective hemostasis, and the pulsed energy delivery may offer advantages in tissue control, precision, and intraoperative hemostasis. However, adequately powered prospective randomized trials directly comparing ThuLEP and HoLEP remain scarce, and patient-reported outcomes such as IPSS and ICIQ-SF are insufficiently studied.

Objectives The primary objective is to compare the improvement of LUTS between ThuLEP and HoLEP, measured as the change in IPSS from baseline to 12 months postoperatively. Secondary objectives include comparison of functional outcomes (Qmax, post-void residual urine), urinary continence (ICIQ-SF), erectile function (IIEF), perioperative parameters (operative time, laser time, blood loss, catheter indwelling time, length of hospital stay), complication rates (Clavien-Dindo), and re-intervention and re-catheterization rates.

Design Prospective, randomized, single-blind (participant-blinded), interventional comparative trial with 1:1 allocation to ThuLEP or HoLEP. Randomization is performed using sealed envelopes drawn preoperatively. Follow-up duration is 12 months per participant.

Study procedures After establishing the indication for surgical treatment of BPS, patients are screened and informed. Following written informed consent, patients are randomized. Baseline assessment (IPSS, Qmax, post-void residual urine, IIEF, ICIQ-SF) is performed the day before surgery. Surgery is performed according to randomization. Clinical baseline data (laboratory parameters, age, medications, comorbidities) and perioperative data (operative time, resection weight, laser energy) are extracted from operative and medical records. Postoperative assessments are performed at discharge and at 3, 6, and 12 months in the urology outpatient clinic, where patients are scheduled for follow-up visits.

Sample size Sample size calculation is based on the primary endpoint ΔIPSS. Assuming a clinically relevant difference of 5 IPSS points, a standard deviation of 7 points, a power of 80-90%, and a significance level of α = 0.05, approximately 64-86 patients per group are required. Allowing for a 10% drop-out rate, a total of 150 patients will be enrolled.

Risk-benefit Both surgical techniques are established, guideline-concordant treatments of BPS. Participation in the study does not introduce additional procedural risks. A potential benefit is the optimization of individualized treatment strategies for future patients.

Data management Data processing follows medical confidentiality and data protection regulations. Patient data are pseudonymized using an automatically generated code linked to name and date of birth; the decoding key is accessible only to the study team. Data are stored exclusively on secure computers within the hospital network and retained for a maximum of 10 years. No biological material is collected. No data transfer to third parties is planned. Participants may request deletion of their data at any time.

03

Conditions studied

  • BPH (Benign Prostatic Hyperplasia)

Browse trials for

Keywords

  • BPH
  • BPS
  • Enculeation
  • Prostate
  • Laser
  • HOLEP
  • THULEP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, age ≥ 18 years
  • benign prostatic syndrome (BPS) with an established indication for surgical treatment
  • International Prostate Symptom Score (IPSS) ≥ 8
  • Prostate volume > 40 ml
  • Signed written

Exclusion criteria

Exclusion Criteria:

  • Proven or suspected prostate cancer
  • Previous surgery of the prostate or urethra
  • Neurogenic bladder dysfunction
  • Anticoagulation therapy that cannot be paused perioperatively
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    ThuLEP Arm

    Thulium Laser Enucleation of the Prostate using a pulsed thulium laser system (wavelength approximately 2013 nm). The enucleation is performed according to the institutional standard operating procedure.

    Procedure: Thulium Laser Enucleation of the Prostate (ThuLEP)

  • Active comparator
    HoLEP Arm

    Holmium Laser Enucleation of the Prostate using a holmium:YAG laser system. Considered the current reference standard for endoscopic enucleation of the prostate.

    Procedure: Holmium Laser Enucleation of the Prostate (HoLEP)

Interventions

  • ProcedureThulium Laser Enucleation of the Prostate (ThuLEP)

    Endoscopic enucleation of the prostatic adenoma with a pulsed thulium laser; performed in arm 1

  • ProcedureHolmium Laser Enucleation of the Prostate (HoLEP)

    Endoscopic enucleation of the prostatic adenoma with a holmium:YAG laser; performed in arm 2

06

What researchers measure

Primary outcomes

  1. Change in International Prostate Symptom Score (IPSS) at 12 months

    The IPSS is a validated 7-item questionnaire assessing lower urinary tract symptoms. Total score ranges from 0 to 35, with higher scores indicating more severe symptoms. The primary endpoint is the difference between baseline IPSS (day before surgery) and IPSS at 12 months postoperatively (ΔIPSS).

    Time frame: Baseline (day before surgery) and 12 months postoperatively

Secondary outcomes

  1. Maximum urinary flow rate (Qmax)

    Peak urinary flow rate assessed by uroflowmetry

    Time frame: Baseline, 3, 6, and 12 months postoperatively

  2. Post-void residual urine volume (PVR)

    Residual urine in the bladder after voiding, measured sonographically (ml)

    Time frame: Baseline, 3, 6, and 12 months postoperatively

  3. Urinary incontinence - ICIQ-SF score

    International Consultation on Incontinence Questionnaire - Short Form. Score range 0-21; higher scores indicate more severe incontinence

    Time frame: Baseline, 3, 6, and 12 months postoperatively

  4. Erectile function - IIEF score

    International Index of Erectile Function (IIEF). Higher scores indicate better erectile function

    Time frame: Baseline, 3, 6, and 12 months postoperatively

  5. Operative time

    Total duration of surgery in minutes

    Time frame: Intraoperative (day of surgery)

  6. Laser time

    Total time of active laser application in minutes

    Time frame: Intraoperative (day of surgery)

  7. Morcellation time

    Time spent morcellating the tissue in minutes

    Time frame: Intraoperative (day of surgery)

  8. Hemoglobin drop

    Difference between preoperative and postoperative day 1 hemoglobin concentration (g/dL)

    Time frame: Preoperative to postoperative day 1

  9. Transfusion rate

    Proportion of participants requiring blood transfusion during the hospital stay

    Time frame: During index hospital admission (typically up to 7 days)

  10. Catheter indwelling time

    Number of days the transurethral catheter remained in place after surgery

    Time frame: From surgery until catheter removal (typically within 7 days)

  11. Length of hospital stay (LOS)

    Number of days from admission to discharge

    Time frame: During index hospital admission (typically up to 7 days)

  12. Perioperative complications - Clavien-Dindo

    Peri- and postoperative complications graded according to the Clavien-Dindo classification

    Time frame: Up to 12 months postoperatively

  13. Re-intervention and re-catheterization rate

    Proportion of participants requiring any re-intervention or re-catheterization for BPH-related indications

    Time frame: Within 12 months postoperatively

  14. Stricture rate (urethra)

    Strictures occurring in the urethra postoperatively

    Time frame: Within 12 months postoperatively

  15. Bladder neck stenosis

    Bladder neck stenosis occurring postoperatively

    Time frame: Within 12 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

Of 155 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 3 months is below that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Jun 2026 → Sep 2026 and primary completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
May 4, 2026
StartActual
Sep 5, 2026was Jun 2026
Primary completionEst.
Dec 30, 2026was Sep 2026
CompletionEst.
Dec 31, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Sep 5, 2026 (actual)
Oct 7, 2026
Primary completion
Sep 30, 2026→Dec 30, 2026
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Start date Jun 1, 2026→Sep 5, 2026 (now actual)
    Primary completion Sep 30, 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07565961
Responsible party
Yannic Volz (Consultant and Assistant Professor for Urology, Ludwig-Maximilians - University of Munich) — Principal investigator
First posted
May 4, 2026
Start date
Sep 5, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Yannic Volz, PD Dr. med.
Contact
yannic.volz@med.uni-muenchen.de
+498944000
Patrick Keller, PD Dr. med.
Contact
patrick.keller@med.uni-muenchen.de
Yannic Volz, PD Dr. med.
study chair · LMU University Hospital
Patrick Keller, PD Dr. med.
study chair · LMU University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion